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Abstract 
The development of selective inhibitors of the clinically relevant human Carbonic Anhydrase (hCA) isoforms IX and XII 
has become a major topic in drug research, due to their deregulation in several types of cancer. Indeed, the selective 
inhibition of these two isoforms, especially with respect to the homeostatic isoform II, holds great promise to develop 
anticancer drugs with limited side effects. Therefore, the development of in silico models able to predict the activity 
and selectivity against the desired isoform(s) is of central interest. In this work, we have developed a series of machine 
learning classification models, trained on high confidence data extracted from ChEMBL, able to predict the activity 
and selectivity profiles of ligands for human Carbonic Anhydrase isoforms II, IX and XII. The training datasets were built 
with a procedure that made use of flexible bioactivity thresholds to obtain well-balanced active and inactive classes. 
We used multiple algorithms and sampling sizes to finally select activity models able to classify active or inactive 
molecules with excellent performances. Remarkably, the results herein reported turned out to be better than those 
obtained by models built with the classic approach of selecting an a priori activity threshold. The sequential applica-
tion of such validated models enables virtual screening to be performed in a fast and more reliable way to predict the 
activity and selectivity profiles against the investigated isoforms.
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Introduction
Human Carbonic Anhydrases (hCA) represent a family 
of targets widely studied for their role both in homeo-
stasis and in a number of pathological conditions [1]. In 
particular, hCA are metalloenzymes, belonging to the 
class of lyases, which catalyze the reversible hydration 




with one proton release  (H+). To date, 15 different iso-
forms of hCA have been identified, 12 of which display 
catalytic activity [1]. All catalytic hCAs present a highly 
conserved inner binding cavity coordinating a zinc ion 
 (Zn2+), necessary for the hydration of carbon dioxide [1]. 
Accordingly, the vast majority of known hCA inhibitors 
present a zinc binding group (ZBG), which is very often a 
primary sulfonamide [2]. The first hCA inhibitors bearing 
a sulfonamide-based ZBG were developed in the 1940s, 
with acetazolamide being the first drug approved in 1954 
[2]. Unfortunately, these molecules tended to have short 
half-lives and to also be active on other isoforms with a 
physiological role in homeostasis, resulting in undesir-
able side effects [2]. In recent years, a considerable inter-
est has arisen for the clinically relevant isoforms IX and 
XII (hCA IX and hCA XII, respectively), which have been 
found to be overexpressed in several types of cancers, 
and especially in hypoxic tumors [3, 4].
The therapeutic relevance of hCA IX and hCA XII as 
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explained as follows. In cancer cells with a hypoxic phe-
notype, the metabolic balance is shifted towards glycoly-
sis under anaerobic conditions, as opposed to oxidative 
phosphorylation (Warbug effect) [5, 6]. This would nor-
mally result in a massive extrusion of lactic acid lowering 
the extracellular pH, and thus providing unfavorable con-
ditions for cell proliferation. However, tumor cells with a 
hypoxic phenotype can overexpress hCA IX and/or hCA 
XII as an adaptive response, which convert carbon diox-
ide produced inside the cell to bicarbonate ion, to reduce 
the acidity in the extracellular space. This allows tumor 
cells to become highly proliferative, invasive, and resist-
ant to several therapies, making them difficult to treat 
with current clinical approaches [5].
Computational approaches have already been applied 
to design hCA inhibitors [7–9]. For example, the FDA 
approved dorzolamid was designed through the appli-
cation of structure-based (SB) approaches [10]. These 
approaches, either alone or in combination, enable the 
modelling of ligands according to their complemen-
tary with the binding site of the investigated target [11]. 
However, although being among the most used screen-
ing techniques in the computational field, SB methods 
are not exempt from limitations. For example, the num-
ber of crystallographic structures of the clinically rel-
evant isoforms hCA IX and hCA XII is significantly lower 
compared to those of hCA II. Likewise, ligand-based 
(LB) methods such as similarity searching approaches 
might present some limitations. For example, they might 
be affected by the adopted similarity measure and the 
selected reference molecule(s), as well as the algorithm 
used for the similarity evaluation [12]. Interestingly, the 
number of small molecules developed and tested against 
these isoforms and made available in public repositories 
is steadily increasing. Such a large amount of data makes 
it possible to use more sophisticated LB techniques. For 
example, very recently Poli et al. reported a fingerprint-
based cheminformatics platform able to successfully 
cluster known hCA inhibitors from PubChem and to 
highlight structure-selectivity relationships [13]. On a 
different note, the use of machine learning approaches 
has become extremely attractive, as testified by the grow-
ing number of studies reported on this topic [14–21], but 
so far, to the best of our knowledge, these methods have 
not been applied to investigate hCA activity and isoform 
selectivity.
In this study, we aimed at training machine learning 
models able to predict the activity and selectivity profiles 
of hCA inhibitors, by using a set of molecular descrip-
tors. In particular, models were trained on classify-
ing groups of molecules with high difference in activity 
between the homeostatic hCA isoform II and the tumor 
related isoforms hCA IX and hCA XII. We used ten 
different classification algorithms to build models, which 
were then tested and validated against previously unseen 
datasets. We obtained excellent levels of performance 
according to different, validated metrics. In particular, 
we found that the use of a probability score as a ranking 
method led to a decrease in the number of false positives, 
yielding models that outperformed those built using pre-
established activity thresholds, built on larger datasets.
Finally, we selected the best models, which were able to 
correctly classify active vs inactive instances in the train-
ing, testing and validations phases. Moreover, from the 
combination of validated activity labels we could predict 
and discuss the selectivity profile of specific examples out 
of the validation dataset. In conclusion, this study pro-
vides evidence that the application of sequential binary 
classification models, combined with the use of probabil-
ity scores, can be used for virtual screening campaigns 
able to recognize with high confidence the most likely 




In this study, we trained and tested machine learning 
models based on molecular descriptors to predict activity 
and selectivity profiles of a set of reported human Car-
bonic Anhydrases (hCAs) inhibitors. To this aim, we first 
generated a curated dataset of bioactivities on the human 
Carbonic Anhydrase targets. In particular, compounds 
with activity reported for hCA II, IX and XII were down-
loaded from the ChEMBL database (release 26, accessed 
on March 20th, 2020) [22]. To ensure that the dataset 
contained curated and comparable data, we took into 
account only annotations that derived from tests on sin-
gle proteins and activities expressed as  Ki and  IC50. This 
procedure enabled the collection of 6,396 unique inhibi-
tors with 18,857 activity records (the dataset downloaded 
from ChEMBL is given as Additional file 1).
Additional filtering was performed on the initial data-
set to retain only molecules with a primary sulfona-
mide zinc binding group (ZBG), which are expected to 
modulate hCAs through the same mechanism of action. 
This operation allowed us to exclude allosteric inhibi-
tors (often binding to the outermost part of the bind-
ing pocket) and compounds bearing uncommon ZBGs, 
which are likely to be less validated. Indeed, the vast 
majority of hCA inhibitors reported in the literature pre-
sent a ZBG based on a primary sulfonamide [2]. Prelimi-
nary analyses showed that around 10% of the compounds 
in the initial dataset have multiple activity records for 
the same target(s), occasionally with different outcomes. 
To remove data that would affect the prediction per-
formances of the training models, we first processed 
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molecules with multiple activity records on the same 
target. In particular, molecules whose standard devia-
tion was lower than 20% of the original mean value were 
retained. The activity of compounds with more than 5 
activity records on the same target and a standard devia-
tion higher than 20% was reported in the dataset as the 
mode of the observed ChEMBL values (see “Methods” 
section). This procedure allowed us to collect an appro-
priate number of compounds for the development of 
the machine learning models. The KNIME workflow 
used to filter and prepare ChEMBL data and the result-
ing processed dataset are given as Additional file  2 and 
Additional file 3, respectively. The total number of mole-
cules for each isoform and their activity distributions are 
reported in Table 1 and Fig. 1, respectively.
As shown in Fig. 1, the number of bioactivities for the 
three isoforms and their distribution are rather uneven. 
In addition, many of the reported activities are shifted 
to values below 100 nM for hCA II, while the number of 
activity data with higher values (“inactive” compounds) is 
considerably low. This issue is even more pronounced for 
isoforms IX and XII, most likely because of the tendency 
not to publish negative results.
As reported in previous studies on other targets [23–
26], the first step to develop accurate machine learning 
models for binary classification should be the definition 
of an activity threshold to split active and inactive classes, 
or alternatively two thresholds to further separate a 
class of intermediate activities. In the absence of spe-
cific activity thresholds reported in previous studies on 
hCA isoforms, we initially classified molecules as active 
or inactive by observing the activities distribution for the 
three isoforms. We established two thresholds, i.e. a mol-
ecule was classified as active when its activity is below 
20 nM, and inactive when the activity is above 100 nM. 
As reported in Table 2, the resulting classes appeared to 
be highly unbalanced, both within the same isoform and 
across the different isoforms. Additional explored activ-
ity thresholds are reported in Additional file 4: Table S1. 
It has been previously reported that training on such 
unbalanced datasets would negatively affect the ability of 
the machine learning models in predicting both classes 
(“active” vs “inactive”) with equal performance [27].
Therefore, we applied a sampling procedure, unrelated 
to the choice of fixed bioactivity thresholds, to address 
this issue. In particular, the activities obtained through 
the merge and filtration process were first ranked in 
ascending order. Then, we performed sampling of groups 
formed by equal size of the first N molecules (active 
class) and the last N molecules (inactive class) for each 
of the three isoforms. Table 3 shows how maximum and 
minimum values for each class vary with the sampling 
size N values.
For instance, a marked difference of activity between 
active and the inactive classes at all sampling sizes was 
noted for isoform II. Although less evident, the differ-
ence is also present in the sampled groups for isoform IX. 
On the contrary, when N sampling sizes higher than 250 
were used for isoform XII, the flexible threshold to define 
a compound as inactive became less than 100 nM, owing 
Table 1 Number of bioactivities per hCA isoform in the processed dataset
ChEMBL Target ID Target name Target organism Molecules in the 
initial dataset
CHEMBL205 Carbonic anhydrase II Homo sapiens 4166
CHEMBL3594 Carbonic anhydrase IX Homo sapiens 2310
CHEMBL3242 Carbonic anhydrase XII Homo sapiens 1654
Fig. 1 Activity distributions for the hCA II, hCA IX and hCA XII 
ChEMBL inhibitors with a primary sulfonamide ZBG, after merging 
and filtration of the outliers
Table 2 Number of active and inactive compounds for each 
isoform, according to fixed activity thresholds
We considered active compounds those with reported activity in the processed 
dataset below 20 nM, while those with activity above 100 nM were considered 
as inactives
Activity values hCA II (count) hCA IX (count) hCA XII (count)




≥ nM (inactive) 1245 733 246
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to the limited number of compounds with high reported 
 Ki or  IC50 values on ChEMBL.
We then built machine learning models using Python 
scikit-learn modules [28]. RDKit molecular descriptors 
were used to describe each molecule of the initial dataset 
[29]. The baseline dataset included 118 descriptors (fea-
tures). Two additional datasets were created by filtering 
the most correlated features, resulting in the PCC = 0.95 
dataset (92 descriptors) and PCC = 0.75 dataset (57 
descriptors) (see Methods). For each isoform, an auto-
mated procedure was developed to create a dataset con-
taining the first N and the last N molecules according to 
the reported bioactivity data. We set apart 25% of the ini-
tial dataset to be used in the testing phase, preserving the 
distribution of the two classes (see Fig.  2). The remain-
ing 75% was subjected to a cross-validation procedure 
for each of the selected 10 classification algorithms. The 
prediction performances were estimated as averages of 
accuracy and Matthews Correlation Coefficient (MCC), 
and the standard deviation related to obtained results 
was also determined. Moreover, we also considered pre-
cision and recall scores as additional indexes to further 
evaluate the predictive performances of the models. We 
investigated N sampling sizes ranging from 150 to 700, 
with increments of 50 units for all isoforms.
The overall results of the training phase are reported 
in Additional file  4: Tables S2 and S3, in terms of aver-
aged accuracy and MCC values, respectively. Then, the 
ability of the models to correctly predict the previously 
unseen data was assessed (testing phase). In this phase, 
models were trained on the 75% of the initial dataset, 
and predictions were made on the remaining 25%, which 
was set apart at the beginning. The complete results of 
the testing phase are reported in the Additional file  4: 
Tables S4 and S5. Models built with the application of a 
Pearson Correlation Coefficient threshold of 0.95 (herein 
referred as “PCC = 0.95”) to filter the most correlated 
features yielded slightly, but consistently better results 
with respect to the baseline and PCC = 0.75 models (see 
Additional file 4: Tables S2–S5). This shows that several 
Table 3 Number of instances in "active" and "inactive" classes by sampling groups of equal size (group size = N)
The ratio between the last active and first inactive compounds is reported in italics in the “Closest ratio” column
N hCA II hCA IX hCA XII
Max Active (nM) Min Inactive (nM) Closest ratio Max Active (nM) Min 
Inactive 
(nM)







150 0.83 10,000 12,048.19 2.8 1213 433.21 1.8 397 220.56
200 1 4550 4550.00 3.429 710 207.06 2.7 200 74.07
250 1.4 2675 1910.71 4.5 464 103.11 3.4 96.7 28.44
300 1.7 1290 758.82 5.2 360 69.23 3.94 82.3 20.89
350 2 860 430.00 6 282 47.00 4.7 73.5 15.64
400 2.1 711 338.57 6.6 248 37.58 5.4 62.1 11.50
450 2.6 626 240.77 7.3 220 30.14 5.9 53.1 9.00
500 3 550 183.33 7.9 190.5 24.11 6.4 45.4 7.09
550 3.3 484 146.67 8.5 162 19.06 7 39.1 5.59
600 3.845 431 112.09 9.1 137.1 15.07 7.5 33.25 4.43
650 4.2 390 92.86 9.8 121 12.35 8.1 27.8 3.43
700 4.7 354 75.32 11.7 106 9.06 8.6 21 2.44
750 5 314 62.80 13.5 95 7.04 9.2 15.6 1.70
800 5.2 280 53.85 16 86.4 5.40 10 12 1.20
850 5.6 258 46.07 18 78.1 4.34 – – –
900 6 235 39.17 21 70.3 3.35 – – –
950 6.3 210 33.33 23.2 63.5 2.74 – – –
1000 6.8 180.2 26.50 25.4 54 2.13 – – –
1100 7.5 133 17.73 31.6 41 1.30 – – –
1200 8.1 106 13.09 – – – – – –
1300 9 92 10.22 – – – – – –
1400 10 80 8.00 – – – – – –
1500 11 70 6.36 – – – – – –
1600 13 60 4.62 – – – – – –
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features in the initial dataset were redundant and only 
provided noise to the training models, while others were 
significant and informative. Similar results were also 
obtained when considering precision and recall score 
indexes (Additional file 4: Figure S1).
A graphical visualization of the results obtained in the 
testing phase on the PCC = 0.95 dataset is shown for each 
hCA isoform in Fig.  3. In each plot of Fig.  3, the True 
Positives (correctly predicted actives, %TP), True Nega-
tives (correctly predicted inactives, %TN), False Positives 
(inactives mislabeled as actives, %FP) and False Negatives 
(actives mislabeled as inactives, %FN) rates are reported 
in terms of percentages variation, per group size (N) and 
algorithm employed. Moreover, Fig.  3 also reports the 
Fig. 2 a Partitioning of initial data into training, testing and validation datasets. For each isoform, the best N molecules were sampled in the “active” 
class, and the worst N in the “inactive” class, according to flexible bioactivity thresholds. Molecules not sampled in the training or testing dataset, and 
with bioactivities lower than 20 nM or higher than 100 nM were used as a validation dataset. b Workflow for machine learning experiments: 75% 
of the initial dataset was subjected to a tenfold cross validation (training phase) and used to train models against a previously unseen 25% (testing 
phase). Finally, the whole initial dataset was used to train models to predict the validation dataset (validation phase)
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variation in the accuracy score across the different mod-
els (the black line in the plot) and group sizes, as resulting 
from the sum of the %TP and %TN.
As shown in Fig. 3 and Additional file 4: Table S4, the 
accuracy values obtained in the testing phase were on 
average higher than 70% for most methods, with the 
exception of Support Vector Machines (SVM) and Naïve 
Bayes (NB) algorithms. Tree-based algorithms, and espe-
cially ensemble methods (Random Forest, Extra Tree, 
Gradient Boosting), proved to be the most efficient, with 
accuracy scores ranging from 0.77 to 0.97.
For isoforms II and IX the ability to correctly discrimi-
nate active from inactive compounds was only marginally 
affected by the increasing size of the sampling classes. 
On the contrary, isoform XII experienced a progressive 
decrease in the performance for all algorithms as the 
sampling size increased. This was consistent with the fact 
that an extensive sampling on the dataset curated for this 
isoform, provided “active” and “inactive” classes with low 
activity differences (see Table 3).
Similar trends were observed in the prediction perfor-
mances during the training phase of the models (Addi-
tional file  4). Interestingly, in some cases the models 
built in the testing phase provided slightly better results 
than those of the training phase. The chemical similar-
ity between the molecules in the training and testing 
datasets, evaluated by means of the RDKit Atom Pair 
fingerprints [30], provided Tanimoto coefficients (Tc) 
below 0.336 (a commonly accepted similarity threshold 
according to the RDKit documentation [31]). Thus, the 
higher performances in correctly classifying molecules 
of the test dataset appear to be more dependent on the 
quantity of data the models can learn from, rather than 
to a higher chemical similarity between the molecules 
Fig. 3 Building models to predict activity classes: representation of variations of TP, TN, FP, and FN percentages as group size (N), the algorithm 
used, and the investigated isoform vary for trained models in the testing phase. All models were built applying a Pearson Correlation Coefficient 
threshold of 0.95 to filter the most correlated features. The black line represents overall accuracy
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in the datasets. Notably, MCC values (Additional file  4: 
Table S5) calculated for both training and testing phases 
confirmed the previously observed trends, and allowed 
us to identify Random Forest (RF), and its more rand-
omized variant Extra Tree (ET), as the best algorithms.
Afterwards, we compared the obtained results with 
those resulting from the use of pre-established activity 
thresholds (herein referred as “traditional method”) [26]. 
To this aim, we repeated the same training–testing pro-
cedure on 10 algorithms, this time by labeling as “active” 
the molecules with activity below 20  nM, and as “inac-
tive” molecules with activity above 100  nM (Table  2). 
These analyses showed that the Extra Tree algorithm was 
able to provide satisfactory performances also in the “tra-
ditional method”, as reported in Additional file 4: Tables 
S6–S7, but the accuracy and MCC metrics evaluated 
for the three best models were considerably lower with 
respect to those obtained with the flexible bioactivity 
thresholds proposed here (Table  4). Additional calcula-
tions using the fixed threshold method for the Extra Tree 
algorithm can be found in Additional file  4: Table  S8, 
where molecules were labeled as “active” or “inactive”, 
according to different activity thresholds.
A further validation experiment (herein referred to as 
“external validation”) was also performed on a set of mol-
ecules, not present in the initial training dataset, having 
reported activity values below 20 nM, or above 100 nM 
(see Fig.  2). This allowed us to evaluate how the devel-
oped models would perform under screening-like con-
ditions. In particular, we first trained the models on the 
initial dataset, sampled with the first N and the last N 
molecules. Then, models were asked to classify the vali-
dation dataset by using the Extra Tree algorithm, which 
performed best in the previous tasks. In this phase, we 
used a probability score to assess the confidence level 
of the label predictions (“active” or “inactive”), as imple-
mented in scikit-learn (see Methods). In our analyses, 
probability scores close to 1.0 corresponded to highly 
confident model predictions, while values closer to 0.5 
were considered less reliable. Moreover, as done in the 
previous analyses, we repeated the predictions for 10 
independent experiments and then we averaged the pre-
dicted labels and probability scores to further strengthen 
the results (see Methods). Interestingly, results of these 
analyses provided low standard deviations (see Addi-
tional file  4: Table  S9), suggesting that the randomness 
inherent in the Extra Tree algorithm itself is well bal-
anced, and that the predicted outcomes should be con-
sidered of high confidence.
For each isoform, the validation results at different N 
sampling sizes (black dotted line), and the values strati-
fied per the different probability score (colored lines) are 
reported in terms of accuracy and MCC in Fig. 4 (panels a 
and b), respectively. Data points for the hCA XII isoform 
are missing at sampling sizes (N) higher than 250 due to 
the absence of molecules with bioactivity higher than 
100 nM (“inactive” instances) in the validation dataset.
Interestingly, we observed that the accuracy and MCC 
values increase for all isoforms and groups, according to 
confidence level in the label prediction. The same trends 
could be observed also for precision and recall metrics 
(Additional file 4: Figure S2). This clearly shows that the 
use of probability scores to estimate the reliability of the 
predictions significantly reduced the number of FP and 
FN in the performed study.
As shown in Fig.  4 (panels a and b), models valida-
tion provided similar trends for hCA II and IX in terms 
of accuracy and MCC, the best results being at sampling 
sizes N = 350 and N = 450, respectively (see Table  5). 
Different results were obtained for hCA XII, in which 
the low number of activity records labeled as “inactive” 
forced us to choose small values of N for this isoform. 
Notwithstanding, hCA XII models trained with a sam-
pling size equal to 150 allowed us to obtain accuracy 
and MCC scores of 0.90 and 0.71, respectively, when 
predictions with the highest probability score were con-
sidered (see Table 5). Remarkably, these values are supe-
rior to those obtained with the “traditional method” (see 
Table 4). These results show that although the proposed 
model was built with only 300 instances, with activities 
below 1.98 nM or above 397 nM (N = 150, see Table 3), 
it was able to outperform “traditional models” built on a 
larger dataset of molecules.
Finally, we investigated whether the obtained perfor-
mances could be dependent on the chemical similar-
ity between molecules in the training and validation 
datasets. To do this, we first extracted two subsets of 
molecules from the validation dataset, according to the 
degree of 2D similarity with the compounds in the train-
ing dataset. Ligands similarity was calculated by using 
the RDKit Atom Pair fingerprints (APfp) (see Meth-
ods), which are considered among the best types of 
Table 4 Comparison of testing phase results between different 
sampling approaches
The “flexible threshold method” refers to the sampling method proposed in this 
work. The “fixed threshold method” refers to the traditional method of sampling 
the active vs inactive class by choosing fixed bioactivity thresholds (in this case, 
activity < 20 nM (active class) or ≥ 100 nM (inactive class)
Isoform Flexible threshold method Fixed threshold method
Accuracy (Max) MCC (Max) Accuracy (Max) MCC (Max)
hCA II 0.86 ± 0.08 0.74 ± 0.15 0.73 ± 0.10 0.45 ± 0.17
hCA IX 0.80 ± 0.10 0.62 ± 0.18 0.73 ± 0.07 0.41 ± 0.18
hCA XII 0.81 ± 0.08 0.92 ± 0.03 0.82 ± 0.15 0.47 ± 0.16
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fingerprints to correctly rank closely related analogues 
[32]. A Tanimoto coefficient (Tc) equal to 0.336 was used 
as a threshold to define the subsets containing molecules 
with either high  (TcAPfp ≥  0.336) or low  (TcAPfp < 0.336) 
similarity to training dataset instances, respectively, as 
reported in the RDKit documentation. Then, we com-
pared the accuracy, MCC, precision and recall values at 
probability scores equal to 1.0 for each subset, as shown 
in Table  6. The complete results of this analysis can be 
found in Additional file 4: Table S10. Interestingly, these 
analyses provided similar levels of prediction perfor-
mance for both datasets on hCA II models, the obtained 
MCC scores being 0.75 for both subsets. Different results 
were obtained for hCA IX models, which provided MCC 
scores of 0.58 and 0.89 in the predictions of “similar” and 
“not similar” datasets, respectively, and for hCA XII with 
MCC scores of 0.48 and 0.76 in the “similar” and “not 
similar” dataset, respectively.
Altogether, results of the performed analyses show 
that models built with the flexible bioactivity threshold 
sampling method performed well, both in the training 
and testing phases. Moreover, the accuracy and MCC 
scores achieved in the prediction performances proves 
that models are able to generalize outside the initial data-
set characteristics, and that the use of probability scores 
allows to refine results and drastically reduce the number 
of inaccurate predictions. The application of probability 
scores can also help assessing model confidence in the 
predictions of molecules with moderate or intermediate 
activities against agiven isoform, which are more diffi-
cult to classify. In the light of this, we envisage that such 
a score can in principle improve the prediction perfor-
mance also in virtual screening conditions, and thus help 
prioritizing compounds for experimental testing.
Python scripts used to perform all training, testing and 
validation phases are made available as Additional file 5 
Fig. 4 External validation of the Extra Tree models: graphical representation of a accuracy and b MCC at different values of the probability score. The 
overall accuracy and MCC values for all probability label are reported as a black dotted line. Missing datapoints in panel B correspond to validation 
datasets were no “inactive” instance could be found, and therefore MCC could not be calculated
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Table 5 Accuracy, MCC, precision and recall values for best models in the external validation phase
Results are averaged on 10 independent experiments and then rounded to the nearest integer value. Performance metrics are reported in italics
TP true positives, FN false negatives, FP false positives and TN true negatives
Probability score Overall 0.6 0.7 0.8 0.9 1
hCA II, N = 350
TP 782 151 223 131 150 127
FN 741 279 228 167 48 18
FP 204 70 103 17 5 9
TN 683 185 192 110 125 70
Accuracy 0.61 0.49 0.56 0.57 0.84 0.88
MCC 0.28 0.08 0.14 0.29 0.70 0.75
Precision 0.79 0.68 0.68 0.89 0.97 0.93
Recall 0.51 0.35 0.49 0.44 0.76 0.88
hCA IX, N = 450
TP 326 46 103 75 59 43
FN 110 46 29 15 13 6
FP 61 15 20 11 8 7
TN 212 38 58 32 46 37
Accuracy 0.76 0.58 0.77 0.80 0.83 0.86
MCC 0.51 0.21 0.51 0.57 0.67 0.72
Precision 0.84 0.75 0.84 0.87 0.88 0.86
Recall 0.75 0.50 0.78 0.83 0.82 0.88
hCA XII, N = 150
TP 524 88 183 134 55 64
FN 271 94 116 35 20 6
FP 32 7 13 7 4 1
TN 63 20 12 4 19 8
Accuracy 0.66 0.52 0.60 0.77 0.76 0.91
MCC 0.21 0.15 0.05 0.09 0.48 0.67
Precision 0.94 0.93 0.93 0.95 0.93 0.98
Recall 0.66 0.48 0.61 0.79 0.73 0.91
Table 6 Results of the validation phase with probability score equal to 1.0. Performance prediction statistics are reported for the two 
subsets (“similar” and “not similar”) extracted from the validation dataset
Similarity with respect to training dataset was calculated to select similar (“similar”) or dissimilar (“not similar”) subsets. Performance metrics are reported in italics
TP FN FP TN Accuracy MCC Precision Recall
hCA II, N = 350
Not similar 112 17 6 58 0.88 0.75 0.87 0.95
Similar 15 1 3 12 0.87 0.75 0.94 0.83
hCA IX, N = 450
Not similar 26 1 1 12 0.95 0.89 0.96 0.96
Similar 17 5 6 25 0.79 0.58 0.77 0.74
hCA XII, N = 150
Not similar 19 3 0 6 0.89 0.76 0.86 1.00
Similar 45 3 1 2 0.92 0.48 0.94 0.98
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and Additional file 6. The KNIME workflow used to ana-
lyze results is available as Additional file 7.
Selectivity profiling
Having developed a model able to accurately discrimi-
nate active from inactive compounds, we then moved 
on evaluating whether the sequential application of our 
models was able to predict the known selectivity profile 
of ligands for the three hCA isoforms, i.e. II vs IX and II 
vs XII. In line with previous investigations [26, 33], we 
defined the selectivity profile of a compound by combin-
ing activity labels predicted on binary models on each 
hCA isoform.
Table 7 shows the outcomes of activity models and the 
final selectivity profiles thus determined. Therapeuti-
cally relevant classes (molecules predicted to be selective 
for either hCA IX or XII over hCA II) are highlighted in 
bold.
To evaluate whether the sequential application of sepa-
rate hCA binary models was able to correctly predict the 
selectivity profile of the ligands in the dataset, the results 
previously obtained in the validation phase (see Table 5) 
were analyzed. Figure  5 reports few examples of the 
compounds resulting from the applied machine learn-
ing models. In the reported examples, the ability of the 
Extra Tree models to recognize selective inhibitors out 
of a series of related compounds is highlighted. In par-
ticular, the first four examples (i.e., CHEMBL3589744, 
CHEMBL3589808, CHEMBL3765128 and 
CHEMBL3765561) in Fig.  5 were correctly recognized 
as weak hCA II inhibitors, i.e. belonging to the inac-
tive class, according to the defined thresholds. Moreo-
ver, activity predictions made for hCA IX and hCA XII 
were also correct, identifying these molecules as potent 
and selective hCA XII inhibitors. Missing predictions for 
some models are due to the fact that the molecules were 
sampled in the training dataset for that specific isoform.
Interestingly, our models were also able to correctly 
predict the different activity profile of molecules sharing a 
common scaffold, as reported for the pair of compounds 
CHEMBL4284307 and CHEMBL4292591. As shown in 
the lower part of Fig. 5, these molecules present different 
substituents on the phenyl ring, which in turn account 
for different molecular descriptors. Nevertheless, the 
molecules were correctly predicted to be selective for iso-
forms IX and XII, in agreement with experimental data 
reported in the ChEMBL database.
These examples show that our models, although being 
trained on very focused and small groups, are not strictly 
related to the activity values of the initial datasets (see 
Table 3). Indeed, they proved to be able to generalize and 
identify the features that make the "active" molecules (i.e., 
strong binders), different from the "inactives" (i.e., very 
weak, or not binders). Such a feature makes our approach 
appealing to be potentially applied also to other target 
families with a limited number of reported modulators, 
and for screening commercial databases to retain mol-
ecules that are predicted to be active on the isoform(s), or 
target(s), of interest.
Conclusions
In this work, we trained a series of predictive machine 
learning classification models from bioactivity data 
reported on hCA II, hCA IX and hCA XII within 
ChEMBL. In particular, we first downloaded activ-
ity records related to the human Carbonic anhydrase 
isoforms II, IX and XII from the ChEMBL database 
(release 26, accessed on March 20th, 2020), and then 
processed them to obtain an initial dataset of high con-
fidence data. We calculated a set of 92 low-correlated 
molecular descriptors to characterize each molecule. 
We then designed a sampling procedure to build bal-
anced active/inactive classes with the N best and worst 
compounds according to activity values. A total of 360 
models were built for each of the three hCA isoforms, 
using 12 sampling sizes, 10 different classification algo-
rithms and three feature selection methods. Afterwards, 
we evaluated the model performances using a tenfold 
Table 7 Activity predictions and the corresponding selectivity profiles, potentially obtainable by using the binary activity models
Predicted label hCA II
Active Inactive
hCA IX
Active Non selective Selective for hCA IX over hCA II
Inactive Selective for hCA II over hCA IX Non selective
hCA XII
Active Non selective Selective for hCA XII over hCA II
Inactive Selective for hCA II over hCA XII Non selective
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cross-validation training and testing phases on a dataset 
previously unseen by the model, repeated for 10 inde-
pendent experiments to ensure consistent labels. Moreo-
ver, the models built using the best performing algorithm 
(Extra Tree) were trained and used to classify a validation 
dataset based on molecules not sampled by the chosen 
flexible sampling method.
A probability score, which was calculated and averaged 
for each label, proved to be an efficient scoring metrics to 
rank results and to reduce the percentage of mispredic-
tions. Afterwards, we identified the best sampling sizes 
for models built on each isoform, which ensured excel-
lent performances, both on molecules of the training and 
test datasets, but most importantly on molecules of the 
validation dataset whose bioactivity values fall outside of 
the ranges sampled by our flexible threshold method.
Finally, we discussed the possibility to use the binary 
activity models built on each separated isoform to 
Fig. 5 Examples of the activity predictions on a test set of molecules with reported activities on all investigated isoforms
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predict the selectivity profile of a set of previously unseen 
molecules, and discussed six examples from our valida-
tion dataset based on different chemical scaffolds. This 
allowed us to demonstrate that the appropriate combina-
tion of activity labels enabled us to predict in the correct 
selectivity class similar molecules bearing different sub-
stituents. Such a feature is, for example, highly relevant 
in view of screening novel ligands with the desired selec-
tivity profile, whether they be close analogues or more 
chemically diverse.
These results show that the problem of predicting the 
selectivity profile against the three hCA isoforms can be 
broken down into a succession of binary models trained 
on highly focused data. The best-performing models 
trained to predict the activity labels can be in principle 
employed in an ultra-fast virtual screening, where mol-
ecules predicted with the highest probability scores can 
be confidently selected for further experimental testing. 
Altogether, these results allow us to conclude that the 
combination of activity labels to predict the selectivity 
profile, together with probability scoring of the label con-
fidence, allows for informative and accurate predictions.
All datasets and workflows used in the analysis are 
made available within this article. This approach, which 
can be applied also to other targets with reported known 
ligands, can be therefore easily implemented in a work-
flow suitable for large virtual screening purposes.
Methods
Dataset preparation
The initial dataset of hCA bioactivities was extracted 
from ChEMBL release 26 (accessed on March 20th, 2020) 
[22]. A total of 36,832  Ki,  IC50 and  Kd activity records 
on 12 different isoforms of hCA was downloaded. A 
KNIME [34] workflow was used to create the initial data-
set. In particular, activity records were filtered to retain 
only values reported with nanomolar standard unit, and 
a standard relation type corresponding to “ = ” (certain 
data) or “ > ” (automatically classified as inactive). Moreo-
ver, records with activity values not reported as  IC50 or  Ki 
for the hCA isoforms II, IX and XII were removed. The 
applied filtering criteria allowed the generation of a data-
set of 18,857 records for 6396 unique molecules.
The RDKit library was used to preprocess molecules 
[29], by converting them to SMILES strings. Finally, the 
“RDKit Structure Filter” node was used to retain only 
molecules with a primary sulfonamide as Zinc Bind-
ing Group (ZBG). Mean and standard deviation were 
calculated for the molecules with more than one activ-
ity value reported on the same target. Molecules were 
retained if the standard deviation resulted less than 20% 
of original mean value. Molecules with a standard devia-
tion greater than 20% of the mean were also kept if they 
were reported with more than 5 records on the same tar-
get, but their activity was replaced with the mode of the 
reported values, in the final dataset.
For each molecule, RDKit was used to calculate 118 
different molecular descriptors [35]. Moreover, a proce-
dure to eliminate redundant features was implemented. 
In particular, a correlation matrix was calculated with 
the corr() function in Python. Different values of Pearson 
Correlation Coefficient (PCC) were investigated, and two 
additional datasets were created retaining only features 
that provided PCCs lower than 0.95 (PCC = 0.95 dataset), 
and 0.75 (PCC = 0.75 dataset), with 92 and 57 descriptors 
included, respectively. A list of the original 118 molecular 
descriptors, and the filtered PCC = 0.95 and PCC = 0.75 
subsets can be found in Additional file 4: Table S11.
Implementation of machine learning algorithms
For each isoform (hCA II, hCA IX, hCA XII), the activi-
ties were sorted in ascending order. Afterwards, “active” 
and “inactive” classes were built by sampling the first N 
(active class) and the last N (inactive class) molecules. 
Sampling size N was varied from 150 to 700, using a 50 
unit increment. An additional label was assigned using 
pre-established fixed activity thresholds. In this case, 
molecules with an activity below 20 nM were labeled as 
“active”, while molecules with activities above 100  nM 
were labeled as “inactive”. These labels were then used to 
build a comparative set of models to evaluate differences 
in performance against the proposed flexible bioactivity 
threshold method used in this work.
Python scikit-learn modules [28] were used to build, 
fine-tune and validate all machine learning models. The 
list of 10 supervised classification algorithms chosen in 
this work is reported in Table 8.
The initial dataset was divided into the training and test 
datasets, using a 75:25 ratio. In the training phase, 75% 
Table 8 The 10 classification algorithms implemented in Python 




Linear Discriminant Analysis LDA
K-Nearest Neighbor KNN
Decision Tree CART 
Naïve Bayes NB
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of the total database was subjected to a tenfold cross-
validation to test the baseline prediction. In this phase 
10 stratified subsets were created, 9 of which were used 
to train the model and 1 to test results. This procedure 
was repeated by shuffling the subset used as test. Then, 
in the testing phase, the whole training dataset was used 
to train models, which were subsequently used to pre-
dict the 25% previously withheld testing dataset. 10 inde-
pendent experiments were calculated and averaged in the 
final results.
Metrics used to validate model performance were accu-
racy, precision, recall (ranging from 0 to 1) and Matthews 
Correlation Coefficient (MCC) [36], ranging from − 1 to 
1.
A value of MCC higher than 0.6 was considered to be 
indicative of a good performance of the applied machine 
learning model.
In order to calculate the number of true positives (TP), 
true negatives (TN), false positives (FP) and false nega-
tives (FN), the positive class was set to be correspondent 
to the “active” class in the activity models.
Moreover, a probability value was calculated for every 
prediction, as implemented in algorithm functions in 
scikit-learn, i.e., using the predict_proba function to esti-
mate the confidence level of predicted results. The func-
tion returns a tuple of the type [probability score for class 
A; probability score for class B] for each label, where the 
total sum is 1. Only the highest value for the predicted 
label was retained. Probability scores range from 0 (low-
est confidence) to 1 (highest confidence on the predicted 
label).
In the final step of external validation, models were 
trained on the 100% of the initial dataset, and then used 
to predict the activity label of an additional set of mol-
ecules extracted from ChEMBL with activities below 
20 nM or above 100 nM and not present in the training 
or testing dataset. 10 independent experiments were 
carried out, each of which had a numerical label ("1" 
corresponding to the active class, and "0" correspond-
ing to the inactive class) and a probability confidence 
Accuracy =
TP + TN








TP × TN − FP × FN
√
(TP + FP)(TP + FN )(TN + FP)(TN + FN )
score. Mean and standard deviations were calculated 
for both the activity labels and probability scores, 
which were then rounded to obtain the final predic-
tion. Predicted classification labels were compared with 
the bioactivity values reported in the validation data-
set. Molecules with a reported bioactivity below 20 nM 
were considered as TP if classified as active by the 
models, and as FN if classified as inactive. Conversely, 
molecules with a reported bioactivity above 100  nM 
were considered as FP if classified as active, and as TN 
if classified as inactive. Based on these values, accuracy 
and MCC scores were calculated.
Finally, two subsets were extracted from the valida-
tion dataset. First, molecules in the training and valida-
tion datasets were converted to Atom Pair fingerprints 
(APfp), using the RDKit Python modules [30]. Then, the 
2D similarity between the molecules in the training and 
validation dataset was estimated through the use of the 
Tanimoto coefficient (Tc). For each isoform and N sam-
pling size, the averaged Tc  (TcAPfp) and standard devia-
tions were calculated. Then, the validation dataset was 
grouped in two sets of similar (“similar” subset: mean 
 TcAPfp  ≥ 0.336) and dissimilar (“not similar” subset: mean 
 TcAPfp < 0.336) molecules, according to the averaged simi-
larity with ligands in the training set. The selected thresh-
old of  TcAPfp allowed to select as similar only 10% of 
“drug-like” molecules, randomly selected from ChEMBL, 
according to RDKit documentation [31].
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